Table 1. Open in new tab Demographics by... | Oxford Academic

Table 1.

Open in new tab

Demographics by group.

	NAC	Placebo	Sig.
Male (n, %)	28 (66.7%)	33 (76.7%)	0.39
Years of education^*	12.92 (2.61)	12.77 (3.09)	0.82
Age at testing^*	39.83 (9.19)	39.65 (9.41)	0.98
Age at onset of symptoms^*	24.12 (7.15)	23.87 (6.40)	0.88
Duration of illness since symptom onset^*	19.06 (11.07)	17.70 (9.10)	0.89
Clozapine level ng/ml^*	543.15 (270.14)	541.83 (249.20)	0.98
Total number of medications^*	4.61 (2.80)	4.18 (2.58)	0.38
PANSS negative^*	20.14 (5.52)	18.32 (5.39)	0.60
PANSS positive^*	16.40 (6.55)	15.89 (5.44)	0.60
PANSS general^*	33.89 (8.34)	33.55 (7.00)	0.47
SAFTEE score^*	31.56 (18.59)	36.82 (20.96)	0.26
Extrapyramidal symptoms^*	2.00 (2.62)	1.38 (1.97)	0.25
Schizophrenia/Schizoaffective diagnosis	27/2	30/3	0.93

	NAC	Placebo	Sig.
Male (n, %)	28 (66.7%)	33 (76.7%)	0.39
Years of education^*	12.92 (2.61)	12.77 (3.09)	0.82
Age at testing^*	39.83 (9.19)	39.65 (9.41)	0.98
Age at onset of symptoms^*	24.12 (7.15)	23.87 (6.40)	0.88
Duration of illness since symptom onset^*	19.06 (11.07)	17.70 (9.10)	0.89
Clozapine level ng/ml^*	543.15 (270.14)	541.83 (249.20)	0.98
Total number of medications^*	4.61 (2.80)	4.18 (2.58)	0.38
PANSS negative^*	20.14 (5.52)	18.32 (5.39)	0.60
PANSS positive^*	16.40 (6.55)	15.89 (5.44)	0.60
PANSS general^*	33.89 (8.34)	33.55 (7.00)	0.47
SAFTEE score^*	31.56 (18.59)	36.82 (20.96)	0.26
Extrapyramidal symptoms^*	2.00 (2.62)	1.38 (1.97)	0.25
Schizophrenia/Schizoaffective diagnosis	27/2	30/3	0.93

Note:

Data presented are mean (standard deviation); PANSS: positive and negative symptom syndrome; SAFTEE: systematic inquiry about emergent clinical events.

Table 1.

Open in new tab

Demographics by group.

	NAC	Placebo	Sig.
Male (n, %)	28 (66.7%)	33 (76.7%)	0.39
Years of education^*	12.92 (2.61)	12.77 (3.09)	0.82
Age at testing^*	39.83 (9.19)	39.65 (9.41)	0.98
Age at onset of symptoms^*	24.12 (7.15)	23.87 (6.40)	0.88
Duration of illness since symptom onset^*	19.06 (11.07)	17.70 (9.10)	0.89
Clozapine level ng/ml^*	543.15 (270.14)	541.83 (249.20)	0.98
Total number of medications^*	4.61 (2.80)	4.18 (2.58)	0.38
PANSS negative^*	20.14 (5.52)	18.32 (5.39)	0.60
PANSS positive^*	16.40 (6.55)	15.89 (5.44)	0.60
PANSS general^*	33.89 (8.34)	33.55 (7.00)	0.47
SAFTEE score^*	31.56 (18.59)	36.82 (20.96)	0.26
Extrapyramidal symptoms^*	2.00 (2.62)	1.38 (1.97)	0.25
Schizophrenia/Schizoaffective diagnosis	27/2	30/3	0.93

	NAC	Placebo	Sig.
Male (n, %)	28 (66.7%)	33 (76.7%)	0.39
Years of education^*	12.92 (2.61)	12.77 (3.09)	0.82
Age at testing^*	39.83 (9.19)	39.65 (9.41)	0.98
Age at onset of symptoms^*	24.12 (7.15)	23.87 (6.40)	0.88
Duration of illness since symptom onset^*	19.06 (11.07)	17.70 (9.10)	0.89
Clozapine level ng/ml^*	543.15 (270.14)	541.83 (249.20)	0.98
Total number of medications^*	4.61 (2.80)	4.18 (2.58)	0.38
PANSS negative^*	20.14 (5.52)	18.32 (5.39)	0.60
PANSS positive^*	16.40 (6.55)	15.89 (5.44)	0.60
PANSS general^*	33.89 (8.34)	33.55 (7.00)	0.47
SAFTEE score^*	31.56 (18.59)	36.82 (20.96)	0.26
Extrapyramidal symptoms^*	2.00 (2.62)	1.38 (1.97)	0.25
Schizophrenia/Schizoaffective diagnosis	27/2	30/3	0.93

Note:

Data presented are mean (standard deviation); PANSS: positive and negative symptom syndrome; SAFTEE: systematic inquiry about emergent clinical events.